Treatment Category Profile

Treatment Name:	Recentin	Known as: Also Known As:	Cediranib
Treatment Type:	Multi-Targeted	Status:	FDA Approved (phase II)
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration. Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway. On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.

   Articles related to this Treatment

	1 Cediranib Demonstrates Safe, Well Tolerated Antitumour Activity in Patients With Advanced Renal Cell Carcinoma Doctor's Guide Dec 1, 2009